News

The FDA’s office of generic drugs has determined the Ranbaxy formulation of nitrofurantoin monohydrate/macrocrystals capsules 100mg to be bioequivalent and have the same therapeutic effect as that of

As an interim step, the company will establish a Level I program of American depositary receipts (ADRs) to enable dollar-denominated trading of its ordinary shares prior to the

Bacterial superantigens are among the most lethal of toxins that can potentially be used as bioweapons. Callisto’s lead monoclonal antibody (Mab) and antagonist peptide are being developed to

Nexium IV (esomeprazole magnesium) is now approved as an intravenous infusion or injection for the short-term treatment of gastroesophageal reflux disease (GERD) patients, with a history of erosive

The filing is the first step in evaluating the potential of AMD3100, a stem cell mobilizer, to help repair damaged heart tissue in patients who have suffered heart

This drug candidate, an antagonist of the Hedgehog signaling pathway, is being developed to treat basal cell carcinoma, the most common form of all human cancers. It was

The FDA approved Zyflo in 1996 for the prevention and chronic treatment of asthma in patients 12 years of age and older. Critical Therapeutics in-licensed worldwide rights to

Under the agreement, Technology Partnerships Canada (TPC) will invest up to $9.3 million in the Migenix’ R&D activities related to MX-2401, a novel lipopeptide candidate in preclinical development

Upon publication of the final rule, Sepracor will commence full-scale commercial launch of Lunesta (eszopiclone). The company expects Lunesta to be widely available by prescription in pharmacies within